Skip to main content

Venous Thromboembolism clinical trials at UCSF

2 in progress, 1 open to eligible people

Showing trials for
  • Apixaban for the Acute Treatment of Venous Thromboembolism in Children

    open to eligible people ages up to 17 years

    To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

    Oakland, California and other locations

  • Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

    Sorry, in progress, not accepting new patients

    The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.

    San Francisco, California and other locations

Our lead scientists for Venous Thromboembolism research studies include .

Last updated: